Jason JD - Neumora Therapeutics, Chief Officer
| NMRA Stock | 9.80 0.14 1.41% |
Executive
Jason JD is Chief Officer of Neumora Therapeutics, Common
| Age | 50 |
| Address | 490 Arsenal Way, Watertown, MA, United States, 02472 |
| Phone | 857 760 0900 |
| Web | https://www.neumoratx.com |
Neumora Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.3775) % which means that it has lost $0.3775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7708) %, meaning that it created substantial loss on money invested by shareholders. Neumora Therapeutics,'s management efficiency ratios could be used to measure how well Neumora Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. As of December 4, 2024, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.42. The current year's Other Assets is expected to grow to about 5.1 M, whereas Total Assets are forecasted to decline to about 340.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Francis Giglio | Lincoln Educational Services | N/A | |
| Kimberly Cornwell | Repligen | N/A | |
| Ginny Ziegler | Pearson PLC ADR | N/A | |
| Giedrius Zunda | Alvotech | N/A | |
| Esq III | Xponential Fitness | 43 | |
| Christina Siniscalchi | Alvotech | N/A | |
| Patrick MD | Centessa Pharmaceuticals PLC | N/A | |
| Danyal Ali | Xponential Fitness | N/A | |
| Jura Mazuran | Xponential Fitness | N/A | |
| James Rasmussen | Lincoln Educational Services | N/A | |
| Jon Snodgres | Repligen | 58 | |
| Adam CBE | Pearson PLC ADR | 60 | |
| April Dovholuk | Centessa Pharmaceuticals PLC | N/A | |
| Ellie MD | Centessa Pharmaceuticals PLC | N/A | |
| Peter Tahinos | Lincoln Educational Services | 65 | |
| Eva Gunnlaugsdottir | Alvotech | N/A | |
| Keith Robinson | Repligen | N/A | |
| Susan English | Lincoln Educational Services | N/A | |
| Albert Hitchcock | Pearson PLC ADR | 59 | |
| Christine Gebski | Repligen | 56 | |
| Neil Whitfield | Repligen | N/A | |
Management Performance
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.38 |
Neumora Therapeutics, Leadership Team
Elected by the shareholders, the Neumora Therapeutics,'s board of directors comprises two types of representatives: Neumora Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neumora. The board's role is to monitor Neumora Therapeutics,'s management team and ensure that shareholders' interests are well served. Neumora Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neumora Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason JD, Chief Officer | ||
| Nicholas Brandon, Chief Officer | ||
| Paul Berns, CoFounder Chairman | ||
| Amy Sullivan, Senior Resources | ||
| John Reynders, Chief Advisor | ||
| Michael Milligan, Principal Officer | ||
| Henry Gosebruch, CEO President | ||
| Robert MD, Head Development | ||
| Lori Houle, Chief Officer | ||
| Jason Duncan, Chief Officer | ||
| Carol Suh, CoFounder COO | ||
| Rajesh Manchanda, Chief Officer | ||
| MD FACP, CoFounder Advisor | ||
| Joshua Pinto, CFO Treasurer |
Neumora Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neumora Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 1.24 B | ||||
| Shares Outstanding | 161.56 M | ||||
| Shares Owned By Insiders | 27.72 % | ||||
| Shares Owned By Institutions | 64.19 % | ||||
| Number Of Shares Shorted | 9.81 M | ||||
| Price To Book | 4.94 X | ||||
| EBITDA | (187.53 M) | ||||
| Net Income | (235.93 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neumora Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics, Common Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neumora Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Return On Assets (0.38) | Return On Equity (0.77) |
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.